Analysis BioNTech Exits Vaccine Manufacturing With 1,860 Job Cuts, Turns Full Attention to Cancer
BioNTech is dismantling the industrial machine it built during the pandemic. After failing to find outside buyers for facilities designed to churn out billions of COVID-19 doses, the Mainz-based company...